These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26116278)

  • 1. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites.
    Zhang T
    Eur J Pharm Sci; 2015 Sep; 77():216-29. PubMed ID: 26116278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
    Duan P; Zhao P; Zhang L
    Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
    Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
    Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
    Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
    Hanke N; Frechen S; Moj D; Britz H; Eissing T; Wendl T; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):647-659. PubMed ID: 30091221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers.
    Bullman J; Nicholls A; Van Landingham K; Fleck R; Vuong A; Miller J; Alexander S; Messenheimer J
    Epilepsia; 2011 Jul; 52(7):1351-8. PubMed ID: 21635243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Incorporation of the in vitro Data (IC50) and in vivo (Cmax) Data for the Prediction of Area Under the Curve (AUC) for Statins using Regression Models Developed for Either Pravastatin or Simvastatin.
    Srinivas NR
    Drug Res (Stuttg); 2016 Aug; 66(8):402-6. PubMed ID: 27144659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms.
    Reig-López J; Merino-Sanjuan M; García-Arieta A; Mangas-Sanjuán V
    Biomed Pharmacother; 2022 Dec; 156():113914. PubMed ID: 36306592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
    Xue C; Zhang X; Cai W
    Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
    Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
    Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
    Lau YY; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
    Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
    Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
    Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
    Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
    Yamazaki S; Johnson TR; Smith BJ
    Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.